blindness from semaglutide Recent studies have begun to explore a possible link between GLP-1 receptor agonists (like semaglutide) and a rare but serious cause of sudden vision loss known as non-arteritic anterior ischemic Comparative ocular outcomes of tirzepatide

Our results showed a clear signal: Patients treated with GLP-1 receptor agonists had significantly lower risks for developing rheumatoid arthritis, gout and osteoarthritis, alongside reduced overall mortality, compared to those receiving DPP-4 inhibitors, Ibis said

Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea

"One direct etiology could be activation of the vagal nerve

Reduction of ischemic brain injury by topical application of insulin-like growth factor-I after transient middle cerebral artery occlusion in rats